Lithium cation

Generic Name: Lithium cation

Drug Type: Small Molecule

Chemical Formula: Li

CAS Number: 7439-93-2

Unique Ingredient Identifier: 8H8Z5UER66

Background: Lithium was used during the 19th century to treat gout. Lithium salts such as lithium carbonate (Li2CO3), lithium citrate, and lithium orotate are mood stabilizers. They are used in the treatment of bipolar disorder, since unlike most other mood altering drugs, they counteract both mania and depression. Lithium can also be used to augment other antidepressant drugs. It is also sometimes prescribed as a preventive treatment for migraine disease and cluster headaches. The active principle in these salts is the lithium ion Li+, which having a smaller diameter, can easily displace K+ and Na+ and even Ca+2, in spite of its greater charge, occupying their sites in several critical neuronal enzymes and neurotransmitter receptors.

Indication: Lithium, in its salt forms, is used as a mood stabilizer and for the treatment of depression and mania. It is most frequently prescribed in the treatment of bipolar disorder.

Associated Conditions: Bipolar Disorder (BD), Depression, Depression, Bipolar, Acute Manic episode

Clinical Trials

Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features

Phase 4

Completed

Conditions: Bipolar Disorder
Schizoaffective Disorder

Interventions: Drug: Olanzapine
Drug: Lithium
Drug: Chlorpromazine

First Posted Date: 2005-09-20

Last Posted Date: 2018-08-31

Lead Sponsor: Melbourne Health

Target Recruit Count: 83

Registration Number: NCT00202293

Locations: 🇦🇺
ORYGEN Youth Health, Parkville, Victoria, Australia

Lithium and Divalproex for the Treatment of Comorbid Rapid Cycling Bipolar Disorder and Substance Abuse Disorder

Phase 3

Completed

Conditions: Bipolar Disorder

Interventions: Drug: Lithium
Drug: Placebo
Drug: Divalproex

First Posted Date: 2005-09-19

Last Posted Date: 2018-02-20

Lead Sponsor: University Hospitals Cleveland Medical Center

Target Recruit Count: 31

Registration Number: NCT00194129

Locations: 🇺🇸
University Hospitals of Cleveland, Cleveland, Ohio, United States

Treatment of Mania Symptoms With Drug Therapy

Phase 3

Completed

Conditions: Schizophrenia
Bipolar Disorder

Interventions: Drug: Divalproex-extended release (DVP-ER)
Drug: Lithium
Drug: Quetiapine

First Posted Date: 2005-09-16

Last Posted Date: 2018-07-17

Lead Sponsor: Palo Alto Veterans Institute for Research

Target Recruit Count: 75

Registration Number: NCT00183443

Locations: 🇺🇸
VA Palo Alto Health Care System, Palo Alto, California, United States

Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Alcohol Dependency in Patients With Bipolar Disorder

Phase 3

Completed

Conditions: Bipolar I Disorder
Alcohol Dependence

First Posted Date: 2005-06-17

Last Posted Date: 2013-01-04

Lead Sponsor: AstraZeneca

Target Recruit Count: 350

Registration Number: NCT00114686

Locations: 🇺🇸
Research Site, Milwaukee, Wisconsin, United States

Efficacy & Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder

Phase 3

Completed

Conditions: Bipolar I Disorder

First Posted Date: 2005-04-08

Last Posted Date: 2009-03-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 710

Registration Number: NCT00107731

Locations: 🇬🇧
Research Site, Welwyn Garden City, United Kingdom

Effects of Lithium and Divalproex'on Brain-Derived Neurotrophic Factor in Huntington's Disease

Phase 2

Completed

Conditions: Huntington's Disease

First Posted Date: 2004-11-03

Last Posted Date: 2008-03-04

Lead Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

Target Recruit Count: 35

Registration Number: NCT00095355

Locations: 🇺🇸
National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States

Effect of Lithium and Divalproex in Alzheimer's Disease

Phase 2

Completed

Conditions: Alzheimer Disease

First Posted Date: 2004-07-26

Last Posted Date: 2008-03-04

Lead Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

Target Recruit Count: 35

Registration Number: NCT00088387

Locations: 🇺🇸
National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States

Treatment of Adolescent Suicide Attempters (TASA)

Phase 2

Completed

Conditions: Suicide, Attempted
Depression

First Posted Date: 2004-03-26

Last Posted Date: 2020-06-22

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 120

Registration Number: NCT00080158

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Columbia University at the New York State Psychiatric Institute, New York, New York, United States
🇺🇸
New York University Child Study Center, New York, New York, United States

and more 3 locations